Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non- BRCA1/2 -Mutant Cancers.

MLA

Yap, Timothy A., et al. “Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non- BRCA1/2 -Mutant Cancers.” Cancer Discovery, vol. 10, no. 10, Oct. 2020, pp. 1528–43. EBSCOhost, https://doi.org/10.1158/2159-8290.CD-20-0163.

APA

Yap, T. A., Kristeleit, R., Michalarea, V., Pettitt, S. J., Lim, J. S. J., Carreira, S., Roda, D., Miller, R., Riisnaes, R., Miranda, S., Figueiredo, I., Rodrigues, D. N., Ward, S., Matthews, R., Parmar, M., Turner, A., Tunariu, N., Chopra, N., Gevensleben, H., … de Bono, J. S. (2020). Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non- BRCA1/2 -Mutant Cancers. Cancer Discovery, 10(10), 1528–1543. https://doi.org/10.1158/2159-8290.CD-20-0163

Chicago

Yap, Timothy A, Rebecca Kristeleit, Vasiliki Michalarea, Stephen J Pettitt, Joline S J Lim, Suzanne Carreira, Desamparados Roda, et al. 2020. “Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non- BRCA1/2 -Mutant Cancers.” Cancer Discovery 10 (10): 1528–43. doi:10.1158/2159-8290.CD-20-0163.